Viewing StudyNCT03564197



Ignite Creation Date: 2024-05-06 @ 11:39 AM
Last Modification Date: 2024-10-26 @ 12:48 PM
Study NCT ID: NCT03564197
Status: RECRUITING
Last Update Posted: 2023-10-18
First Post: 2018-04-11

Brief Title: 18F-PD-L1 PETCT in Nivolumab Treated Patients With NSCLC
Sponsor: The Netherlands Cancer Institute
Organization: The Netherlands Cancer Institute

Conditions & Keywords Data

Conditions:
Name
NSCLC Stage IV
Keywords:
Name View
eligible for first line chemo-immunotherapy first line nivolumabipilimumab or 2nd line and beyond PD-L1 immunotherapy monotherapy View
EGFR WT View
negative EML4-ALK fusion View